Imaging scan for PSMA in prostate cancer
Part of Cancer clinical trials.
This trial uses a special imaging scan (SPECT) to look for a protein called PSMA on prostate cancer cells. The goal is to see how well the imaging agent (99mTc-QULIC-5-P1) finds cancer, which may help guide future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have either suspected, newly diagnosed, or known prostate cancer that shows signs of PSMA (a protein often found on prostate cancer cells) on MRI, CT, or biopsy.
- You are willing to sign a consent form to join the study.
- You are not pregnant.
- You have no known allergy to the imaging agent 99mTc-QULIC-5-P1.
- You have no serious medical issues that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of scan (99mTc-MIP-1404 SPECT/CT) to see how well it can detect the spread of high-risk prostate cancer. It may help doctors better understand the stage of the disease before deciding on treatment.
This trial uses a special imaging scan (SPECT/CT) with a small amount of radioactive tracer to look at prostate cancer. It aims to see how well the scan matches your prostate cancer tests and may help improve detection and assessment.
This trial provides access to a new type of PET/CT scan called 18F-PSMA-1007, which uses a radioactive tracer to find prostate cancer cells that may have spread in the body. The scan may help your doctor plan your treatment more accurately.
This study uses a special type of PET/CT scan called 18F-PSMA-1007 to take detailed pictures of prostate cancer. It's for people who might have prostate cancer, have been diagnosed, or need to check how their cancer is doing after treatment.
This Phase 3 study checks whether a PSMA PET/CT scan (using a special tracer) can help doctors make better decisions for people with prostate cancer after treatment, based on PSA blood test changes. It may help identify whether cancer has spread or how to plan next steps.
This study is looking at how well a special type of PET/CT scan (called PSMA PET/CT) can see cancer in people who have or may have certain tumors. It may help doctors better understand and track the disease.
Hear when a new Prostate Cancer Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.